Tivoxen (Tivozanib 1.34 mg) Capsules | VEGFR Tyrosine Kinase Inhibitor

Medically Reviewed by Dr. Salma Elreedy, MD (Clinical Oncology)

Last Updated: March 10, 2026

Classification: Prescription-Only Medicine (POM)

Prescription-Only Notice: This medication requires a valid prescription, baseline cardiovascular screening, and rigorous clinical monitoring due to its specific mechanism of action and side effect profile.

Tivoxen (tivozanib 1.34 mg) is an oral prescription medication classified as a highly selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor. It has similar active pharmaceutical ingredients to the innovator brand FOTIVDA. In clinical oncology, tivozanib is utilized exclusively for the management of advanced kidney cancer. Unlike front-line therapies, it is specifically designed and approved for heavily pretreated tumors that have progressed despite prior interventions with immunotherapies or other targeted kinase inhibitors.

Oncologist’s Guideline and Patient Query

Who exactly is a candidate for Tivoxen therapy?

According to the FDA approval guide, oncologists prescribe this medication strictly for adult patients diagnosed with relapsed or refractory advanced renal cell carcinoma (RCC). You are only a candidate if your cancer has progressed after you have already received at least two prior systemic therapies. This usually means you have already been treated with immune checkpoint inhibitors or other targeted drugs (like cabozantinib or axitinib) and require a third-line or fourth-line treatment option.

How does this medication work at the cellular level?

Kidney tumors are highly dependent on a blood supply to survive. To grow and spread, the tumor releases a protein called VEGF to stimulate the creation of new blood vessels—a process called angiogenesis.

Tivozanib’s mechanism for RCC involves targeting three specific receptors (VEGFR-1, VEGFR-2, and VEGFR-3) located on the surface of blood vessel cells. By blocking these receptors, the drug effectively cuts off the tumor’s blood supply. This starves the cancer cells of oxygen and nutrients, preventing further tumor progression.

What is the standard dosage and administration protocol?

• Standard Dose: The standard dose is 1.34 mg taken orally once daily.

• The 28-Day Cycle: You will take one capsule daily for 21 consecutive days, followed by exactly 7 days off the medication. This cycle then repeats.

• Administration: You may take the capsule with or without food. Swallow it whole with a glass of water.

• Missed Doses: If you miss a dose, simply skip it and take your next capsule at your regularly scheduled time. Never take two capsules at once to make up for a missed dose.

What are the primary safety concerns and side effects?

Because tivozanib 1.34 mg side effects are closely tied to blood vessel constriction, careful cardiovascular monitoring is mandatory:

• Hypertension (High Blood Pressure): This is the most common and dangerous side effect, affecting nearly half of all patients.

  • Actionable Advice: Your blood pressure must be strictly controlled before initiating therapy. You will need to check your blood pressure daily at home. We will likely prescribe antihypertensive medications to keep your levels safe.

• Hemorrhage and Clotting Risks: Tivozanib increases the risk of bleeding events, as well as arterial thromboembolic events (like stroke or heart attack).

  • Actionable Advice: Seek emergency medical care immediately if you experience chest pain, sudden shortness of breath, or weakness on one side of your body.

• Wound Healing Complications: By inhibiting new blood vessel growth, this drug stops wounds from healing properly.

  • Actionable Advice: If you are scheduled for elective surgery (including major dental work), you must stop taking Tivoxen at least 24 days prior to the procedure. It cannot be restarted until at least two weeks after the surgery.

• Daily Tolerability: Fatigue, hoarseness of voice (dysphonia), and diarrhea are very common.

  • Actionable Advice: Maintain aggressive oral hydration to manage diarrhea, and use over-the-counter loperamide if directed by your clinical team.

What does the clinical trial data show regarding efficacy?

The approval of tivozanib relies on the landmark Phase III TIVO-3 clinical trial data. This study evaluated patients with refractory advanced RCC who had failed at least two prior regimens.

• Progression-Free Survival (PFS): Patients treated with tivozanib demonstrated a median PFS of 5.6 months, compared to 3.9 months for those treated with sorafenib.

• Objective Response Rate (ORR): The ORR for the tivozanib arm was 18%, compared to just 8% in the sorafenib arm. This confirmed that tivozanib provides significant clinical benefit and disease control in heavily pretreated patient populations.

Precautions & Special Populations

• Hepatic Impairment: The liver metabolizes tivozanib. Patients with moderate hepatic impairment require a strict dose reduction to 0.89 mg. The medication is absolutely contraindicated in patients with severe hepatic impairment.

• Pregnancy and Lactation: Tivozanib causes embryo-fetal toxicity. Female patients of reproductive potential (and male patients with female partners of reproductive potential) must use highly effective, non-hormonal contraception during treatment and for at least one month after the final dose. Breastfeeding is strictly prohibited during therapy and for one month following discontinuation.

• Storage Logistics: Store capsules at standard room temperature (20°C to 25°C). Cold-chain refrigeration is not required. Keep the medication in its original blister packaging to protect it from moisture degradation.

Manufacturer Trust & Global Access

Manufacturer Quality Assurance: Tivoxen is manufactured by Everest Pharmaceuticals in Bangladesh. The facility operates in strict adherence to WHO-GMP (World Health Organization – Good Manufacturing Practices) guidelines. To qualify as a reliable FOTIVDA generic equivalent, each batch of Tivoxen undergoes comprehensive comparative dissolution and stability testing to ensure it matches the innovator brand’s pharmacokinetic profile. This guarantees patients receive the exact therapeutic exposure required by clinical guidelines.

Global Supply Chain: Targeted third-line therapies are frequently subject to severe availability delays in certain regions. Tivoxen is accessible to international patients through recognized global distribution channels. This process operates under “Named Patient” or personal importation laws, allowing patients with a verified specialist prescription to import the medication for their own clinical use. All shipments are secured using temperature-logged logistics to ensure structural and chemical stability upon arrival.

Patient Query

Why do I have to take a 7-day break after 21 days of treatment?

The 21-days-on, 7-days-off dosing schedule is strategically designed to allow your body—specifically your cardiovascular system—time to recover from the medication’s toxicities. This brief interruption helps manage side effects like severe high blood pressure without compromising the drug’s overall ability to suppress tumor angiogenesis.

Will I lose all my hair on this medication?

No. Unlike traditional systemic chemotherapy, VEGFR inhibitors like tivozanib do not typically cause total hair loss (alopecia). While you may experience some mild hair thinning, it is not a primary side effect.

Does this medication interact with my other prescriptions?

Yes, significantly. Tivozanib is broken down by the CYP3A4 enzyme in your liver. Taking strong CYP3A4 inducers (such as the antibiotic rifampin or the herbal supplement St. John’s Wort) will drastically reduce the levels of tivozanib in your blood, rendering the cancer treatment ineffective. Always review your complete medication list with your clinical pharmacist.

Is Tivoxen a cost-effective alternative to the innovator brand?

Yes. The tivozanib price in Bangladesh is structurally lower due to the country’s specific pharmaceutical manufacturing regulations and WTO patent exemptions for least-developed countries. However, patients must factor in the logistical costs of secure, temperature-controlled international shipping when sourcing the medication globally.